On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or metastatic solid cancers with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
Presented by: Julia Carnevale, MD, Assistant Professor, University of California San Francisco Covered by: Hannah Abrams, MD “Solid tumors are the next big frontier for cell therapies,” describes Dr. Julia Carnevale,
More
On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or metastatic solid cancers with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
More